Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data
- PMID: 6644555
- DOI: 10.1007/BF01061870
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data
Abstract
Individual pharmacokinetic parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean kinetics, interindividual kinetic variability, and residual variability, including intraindividual variability and measurement error. Individual pharmacokinetics are estimated by fitting a pharmacokinetic model to individual data. Population pharmacokinetic parameters have traditionally been estimated by doing this separately for each individual, and then combining the individual parameter estimates, the Standard Two Stage (STS) approach. Another approach, NONMEM, appropriately pools data across individuals and is therefore less dependent on individual parameter estimates. This study provides further evidence of NONMEM's validity and usefulness by comparing both approaches on simulated routine-type pharmacokinetic data arising from a monoexponential model. The estimates of population parameters (notably those describing interindividual variability) provided by the STS method are poorer than those provided by NONMEM, especially when there is considerable residual error. Further, NONMEM's estimates of population parameters do not require that the data be restricted to special types of routine data such as those obtained only at steady state, or only at peak or trough, nor do the estimates improve with such data. NONMEM's estimates do improve, however, when a data set is enhanced by the addition of single-observation-per-individual type data. Thus, population parameters can be estimated efficiently from data that simulate real clinical pharmacokinetic conditions.
Similar articles
-
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030. J Pharmacokinet Biopharm. 1981. PMID: 7334463
-
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053. J Pharmacokinet Biopharm. 1980. PMID: 7229908
-
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.Drug Metab Rev. 1984;15(1-2):153-71. doi: 10.3109/03602538409015063. Drug Metab Rev. 1984. PMID: 6745080
-
Population pharmacokinetics. Theory and clinical application.Clin Pharmacokinet. 1986 Sep-Oct;11(5):387-401. doi: 10.2165/00003088-198611050-00004. Clin Pharmacokinet. 1986. PMID: 3536257 Review.
-
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):431-446. doi: 10.1007/s10928-020-09695-z. Epub 2020 Jun 13. J Pharmacokinet Pharmacodyn. 2020. PMID: 32535847 Free PMC article. Review.
Cited by
-
Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.Acta Pharmacol Sin. 2012 Nov;33(11):1409-16. doi: 10.1038/aps.2012.71. Epub 2012 Jul 23. Acta Pharmacol Sin. 2012. PMID: 22820910 Free PMC article. Clinical Trial.
-
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.Cancer Prev Res (Phila). 2014 Mar;7(3):283-91. doi: 10.1158/1940-6207.CAPR-13-0215. Epub 2013 Oct 3. Cancer Prev Res (Phila). 2014. PMID: 24085777 Free PMC article. Clinical Trial.
-
Bayesian forecasting in paediatric populations.Clin Pharmacokinet. 1996 Nov;31(5):325-30. doi: 10.2165/00003088-199631050-00001. Clin Pharmacokinet. 1996. PMID: 9118582 Review.
-
Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.J Pharmacokinet Biopharm. 1985 Oct;13(5):515-40. doi: 10.1007/BF01059333. J Pharmacokinet Biopharm. 1985. PMID: 3834066
-
Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Oncologist. 2016 Feb;21(2):220-32. doi: 10.1634/theoncologist.2015-0322. Epub 2015 Dec 14. Oncologist. 2016. PMID: 26668254 Free PMC article. Review.